ALCJ (ALCJ) News
Follow ALCJ (ALCJ) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
CROSSJECT (ALCJ) Adds Three Executives to Board for Scale-Up
CROSSJECT appointed Olivier Lacombe, Didier Morin and Lionel Seltz to its Executive Board, effective immediately, to support industrial scale-up and U.S. commercialization prep.Material DetailsContext by AI AnalystThis m
NEWS | Sep 25, 2026, 05:32 AM UTC
L
CROSSJECT (ALCJ) H1: Cash €12.3M, Adjusted Net Debt €7.8M
CROSSJECT reported H1 2026 results: cash €12.3M after a €15M capital raise, shareholders’ equity €3.0M, adjusted net financial debt €7.8M, and net loss €8.6M. BARDA contract funding was extended to $48.0M through 2030 po
NEWS | Sep 25, 2026, 05:32 AM UTC
L
CROSSJECT strengthens its governance for the industrial and commercial deployment phase
DIJON, FRANCE, September 25, 2026 — 07h30 (CEST) — CROSSJECT (ISIN: FR0011716265; Euronext Growth: ALCJ), a Specialty Pharma company developing innovative solutions for emergency situations based on its proprietary ZENEO
NEWS | Sep 25, 2026, 05:32 AM UTC
L
CROSSJECT Reports Its First-Half 2026 Results and Presents a Significantly Strengthened Financial Structure
Cash and cash equivalents of €12.3 million as of June 30, 2026, a 2.4-fold increase compared to December 31, 2025 (€5.1 million), following the €15 million capital increase completed in May.Shareholders’ equity returned
NEWS | Sep 25, 2026, 05:32 AM UTC